Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.66 |
| ▸ | PTGDR | Q13258 | 8/20 | 0.57 |
| ▸ | TBXA2R | P21731 | 5/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | CCKAR | P32238 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2522365 | 1.00 | PTGDR2 (0.66) | PTGDR2PTGDRTBXA2RCYP2C9ABCB11 | |
| SCHEMBL2516077 | 1.00 | PTGDR2 (0.66) | PTGDR2PTGDRTBXA2RCYP2C9ABCB11 | |
| SCHEMBL2516998 | 0.91 | PTGDR2 (0.55) | PTGDR2PTGDRTBXA2RCYP2C9ABCB11 | |
| SCHEMBL2514401 | 0.91 | PTGDR2 (0.57) | PTGDR2PTGDRTBXA2RCYP2C9ABCB11 | |
| SCHEMBL2515553 | 0.91 | PTGDR2 (0.57) | PTGDR2PTGDRTBXA2RCYP2C9ABCB11 | |
| SCHEMBL2520067 | 0.91 | PTGDR2 (0.57) | PTGDR2PTGDRTBXA2RCYP2C9ABCB11 | |
| SCHEMBL2516995 | 0.91 | PTGDR2 (0.57) | PTGDR2PTGDRTBXA2RCYP2C9ABCB11 | |
| SCHEMBL2516901 | 0.89 | PTGDR2 (0.55) | PTGDR2PTGDRTBXA2RCYP2C9ABCB11 | |
| SCHEMBL2514871 | 0.89 | PTGDR2 (0.53) | PTGDR2PTGDRTBXA2RCYP2C9ABCB11 | |
| SCHEMBL2514410 | 0.88 | PTGDR2 (0.74) | PTGDR2PTGDRTBXA2RCYP2C9ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184496-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-07-19 | — | — | US | claimed |
| US-20120184493-A1 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEEUTICALS, LLC (US) | 2012-07-19 | — | — | US | claimed |
| US-8034826-B2 | Cycloalkane[B]azaindole antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-10-11 | — | — | US | claimed |
| US-20100113503-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | claimed |
| US-8785393-B2 | Ophthalmic pharmaceutical compositions of DP2 receptor antagonists | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120184496-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEUTICALS, LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120184493-A1 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | PANMIRA PHARMACEEUTICALS, LLC (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120027842-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR ADMINISTRATION TO AN EYE | AMIRA PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20110311613-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | AMIRA PHARMACEUTICAL, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-8034826-B2 | Cycloalkane[B]azaindole antagonists of prostaglandin D2 receptors | PANMIRA PHARMACEUTICALS, LLC (US) | 2011-10-11 | — | — | US | disclosed |
| US-20100113503-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184496-A1 | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONISTS | PTGER2, P2RY2, TBXA2R | PTGDR2 5/4885PTGDR 13/4885TBXA2R 3/4885 |
| US-20120184493-A1 | DERMAL FORMULATIONS OF DP2 RECEPTOR ANTAGONISTS | BDKRB2, TRPV2, CYSLTR2 | PTGDR2 14/4885PTGDR 29/4885TBXA2R 7/4885 |
| US-20120027842-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR ADMINISTRATION TO AN EYE | FEN1, SERPINB1, EYA2 | PTGDR2 992/4885PTGDR 1522/4885TBXA2R 353/4885 |
| US-20100113503-A1 | CYCLOALKANE[B]AZAINDOLE ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885PTGDR 1/4885TBXA2R 6/4885 |
| US-20110311613-A1 | TOPICAL FORMULATIONS OF FLAP INHIBITORS FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS | TSLP, SUCLG1, SERPINB1 | PTGDR2 1194/4885PTGDR 1813/4885TBXA2R 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.